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DO PATIENTS AND PHYSICIANS HAVE SIMILAR PREFERENCES CHRONIC
HEPATITIS B TREATMENT OUTCOMES IN TURKEY?
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OBJECTIVES: To quantify patient and physician preferences for therapeutic
tradeoffs involving efficacy, side-effect risks, and evidence uncertainty in chronic
hepatitis B (CHB) treatments. METHODS: Physicians who treat CHB patients and
adult patients with a self-reported physician diagnosis of CHB completed a web-
enabled, discrete-choice experiment survey in Turkey. Both patients and physi-
cians answered 12 treatment-choice questions. Each question required evaluating
a pair of hypothetical CHB medication profiles defined by years the medicine has
been studied, probability that patient’s viral load remains undetectable for five
years with possible reversal of disease progression, five-year treatment-related
risks of a fracture and renal insufficiency, and monthly medication cost. Nested-
logit and random-parameters logit models were used to estimate preference
weights for all attribute levels and the mean relative importance of each attribute.
RESULTS: One hundred fifty-nine physicians and 117 patients completed the sur-
vey in Turkey. Turkish physicians and patients disagreed on the relative impor-
tance of all treatment attributes. Turkish patients ranked years of evidence as the
most important attribute, while Turkish physicians ranked risk of renal insuffi-
ciency as most important. Turkish physicians were willing to accept a 3.2% smaller
increase in fracture risk than patients for an additional year of evidence.
CONCLUSIONS: This is the first study to quantify patient and physician prefer-
ences for CHB treatment attributes and the first study to elicit physician and pa-
tient preferences for years of evidence. We observe different discrepancies be-
tween physician and patient preferences in Turkey. Such discrepancies may
interfere with optimal outcomes if not considered in patient-physician interac-
tions.
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OBJECTIVES: In order to make HIV treatment as effective as possible expert judge-
ment and patient preferences should be attuned. This study aims to elicit patients’
preferences and to compare them to physicians’ assumptions in HIV therapy.
METHODS: In the first part qualitative and quantitative methods were applied to
identify patient preferences. Literature review, focus groups, direct assessment
and a discrete choice experiment were conducted to elicit relevant treatment ob-
jectives from the patients= perspective. In the second part an expert survey with
German physicians (HIV specialists) was used to assess the experts= judgement for
the same objectives. The discrete choice experiment was conducted using a frac-
tional factorial design (two-fold, six attributes) and the statistical data analysis
used random effect logit models. RESULTS: A total of 218 patients and 131 physi-
cians participated in the study. “Emotional quality of life: HIV- infection not obvi-
ous“ was ranked highest both by physicians and patients (coeff. phys.: 4.00, coeff.
pat.: 2.98) followed by “social quality of life: possibility to take part in social life”
(phys.: 1.95, pat.: 1.14) as well as “constitution: less diarrhoea, and nausea” (phys.:
1.93, pat.: 1.61), the latter on second rank for the patients. Less important and
ranking of posts four to six were “life span: maximal increase” (phys.: 0.85, pat.:
0.74), “avoidance of long-term impairment” (phys.: 0.83, pat.: 0.41) and “flexibility
and dosage: treatment-combination of max. 3 tablets per day” (phys.: 0.64, pat.:
0.45). All six attributes had significant effects in both models. CONCLUSIONS: This
enables testing of the concordance between patient and physician valuation of
multiple treatment goals for HIV/AIDS therapy. Experts’ assumptions and patients’
preferences were similar, showing that physicians in HIV treatment are aware of
their patients’ needs and wishes. DCE and direct assessment proved to be valid
instruments to elicit treatment preferences in HIV treatment for experts as well as
for patients.
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SENSITIVITY OF PRO’S IN EVALUATING ADVERSE EVENTS IN PEOPLE
RECEIVING INFLUENZA VACCINATION
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OBJECTIVES: To investigate whether patient reported outcomes could detect dif-
ferences between H1N1 and seasonal influenza vaccinations on adverse events
over a 26 week follow up period.METHODS: In this evaluation, PROBE methodology
consisting of a web-based system supplemented by telephone reporting was used
to collect naturalistic data from people who had received an influenza vaccination
during 2009-2010 season. People were recruited through media advertising and
awareness campaigns in public places and work (West of Scotland). Data collection
on day of immunisation, after 3 days, 8 days, 6 weeks, 12 weeks and 26 weeks. Data
included age, sex, presence or absence of chronic illness, flu vaccination history,
any side effects following vaccination including the duration and action taken.
RESULTS: A total of 1103 vaccine recipients including 134 young children ( 5
years) participated; 694 (63%) received H1N1 vaccine only, 135 (12%) seasonal only,
224 (20%) both H1N1 and seasonal vaccines and 50 (5%) received H1N1 or seasonal
vaccine with a non-influenza vaccine (e.g. travel or pneumococcal). Overall, 70% of
respondents reported experiencing a side effect after vaccination – this includes
pain/discomfort at the injection site and any other side effects. Of the 964 recipi-
ents of an H1N1 vaccine, significantly more (511, 74%) experienced a side effect
compared with those who received only the seasonal flu vaccine (45%, 2-test p
0.001). Multivariate regression analysis revealed that female sex and the H1N1
vaccination were more likely to report any side effect (OR 2.10, p0.001 and OR 4.47,
p0.001 respectively) and age  70 less likely to report (OR 0.29, p0.001).
CONCLUSIONS: People receiving the H1N1 vaccination were more likely to experi-
ence side effects than seasonal influenza vaccination alone. This evaluation shows
that the PROBE methodology quickly and simply captured patient reported out-
come information in a vaccinated population including children.
PIN92
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OBJECTIVES: Primary analysis of REPEAT study showed that 72 weeks treatment
with PegIFN-alfa2a/ribavirin was more effective than 48 weeks in chronic hepatitis
C patients non-responders to previous PegIFN-alfa2b/ribavirin. The aim of this
prospectively planned secondary analysis was to assess patient reported outcomes
(PRO) of re-treatment with PegIFN-alfa2a/ribavirin versus previous treatment with
PegIFN-alfa2b/ribavirin in Spain. METHODS: In REPEAT, 950 non-responders to
PegIFN-alfa2b were randomized to PegIFN-alfa2a 360g/week for 12 weeks, then
180g/week for a further 60 or 36 weeks (Arms A or B, respectively), or PegIFN-
alfa2a 180g/week for 72 or 48 weeks (Arms C or D, respectively); all patients re-
ceived ribavirin 1000-1200mg/day. In this sub-analysis, 100 Spanish patients from
10 centres (Arms A: n40; B: n19; C: n11; D: n30) were administered a two-part
questionnaire: part one was completed at baseline (questions on previous PegIFN-
alfa2b/ribavirin therapy) and part two was completed at end of treatment (ques-
tions on recent PegIFN-alfa2a/ribavirin therapy). The questionnaire included 15
items concerning patient perception of viral load, tolerability of treatment, health
status, management of devices as well as side effects and problems experienced
specifically to one treatment. RESULTS: At baseline, 16% patients reported feeling
good/excellent, 43% fair and 41% poor while receiving PegIFN-alfa2b/ribavirin ver-
sus 30%, 49% and 20%, respectively, at end of re-treatment. Significantly more
patients perceived PegIFN-alfa2a/ribavirin to be associated with better/much bet-
ter effects on viral load, tolerance, health status and handling of devices versus
PegIFN-alfa2b/ribavirin. Problems exclusive to PegIFN-alfa2b/ribavirin were re-
ported in 33% of patients while 17% reported new problems with PegIFN-alfa2a/
ribavirin. With either treatment, 96% of patients reported side effects. Patient-
reported tolerance to PegIFN-alfa2a/ribavirin was similar in all treatment arms,
irrespective of dose (p0.069). CONCLUSIONS: Re-treatment with PegIFN-alfa2a/
ribavirin in Spanish patients improved assessed patient reported outcomes versus
previous treatment with PegIFN-alfa2b/ribavirin. Patients reported good tolerance
even in 72 weeks re-treatment.
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ASSESSMENT OF KNOWLEDGE AND AWARENESS OF HEPATITIS B AMONG
GENERAL PUBLIC IN PAKISTAN
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OBJECTIVES: To evaluate knowledge and awareness of hepatitis B in general pop-
ulation of Quetta, Pakistan.METHODS:A questionnaire-based cross sectional anal-
ysis was designed. A pre-tested and validated questionnaire containing 20 ques-
tions (6 questions for general information, 4 for symptoms, 6 for transmission and
4 for treatment) was used for data abstraction. Stratified groups from 2 towns of the
city aging 18 years and above were approached. Descriptive statistics were used to
describe demographic of the population. Percentages and frequencies were used to
categorize categorical variables, while means and standard deviations were calcu-
lated for the continuous variables. Non parametric tests (Mann-Whitney and
Kruskal Wallis Test) were used where appropriate. Knowledge scored was catego-
rized into good, medium and poor knowledge. All analyses were performed using
SPSS 16.0. RESULTS: Three hundred and ninety individuals were enrolled in the
study with 210 (53.8%) of males. Majority (n178, 45.6%) were categorized in age
group of 18-30 years. The mean knowledge score was calculated as 8.672.730 (out
of 20) and was categorized as poor. Education level, occupation, income level and
locality had significant relation with knowledge scores of the general population
regarding hepatitis B. CONCLUSIONS: This study shows that there is poor level of
knowledge and awareness of hepatitis B in general population of the city. Disease
specific educational and awareness interventional program is recommended.
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ASSESSMENT OF HEALTH RELATED QUALITY OF LIFE (HRQOL) IN HEPATITIS- B
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OBJECTIVES: To evaluate HRQoL in hepatitis B patients attending public hospitals
in Quetta, Pakistan.METHODS:A descriptive study was shaped as a questionnaire-
A282 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 2 3 3 - A 5 1 0
based cross sectional analysis. European Quality of Life scale (EQ-5D) was used for
assessment of HRQoL. Registered Hepatitis B patients aging 18 years and above
were approached. Descriptive statistics were used to describe demographic and
disease related characteristics of the patients. Percentages and frequencies were
used to categorize the categorical variables, while means and standard deviations
were calculated for the continuous variables. Non paramatric tests (Mann-Whitney
and Kruskal Wallis test) were used where appropriate. HRQoL was scored by using
values from UK general population survey. All analyses were performed using SPSS
16.0. RESULTS: Three hundred ninety hepatitis B Patients were enrolled in the
study with 232 (59.5%) of males. Majority (n126, 32.3%) were categorized in age
group of 18-30 years. HRQoL was measured poor in our study patients (0.3498
0.31785) with Visual Analogue Scale score of 59.1510.517. Among all variables,
only gender had significant relation with HRQoL score. CONCLUSIONS: Hepatitis B
has an adverse impact of on patients’ well-being and HRQoL. Patient centric efforts
are recommended to improve patients HRQoL with Hepatitis B.
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THE IMPACT OF INFLUENZA ON IN- AND OUTPATIENTS’ HEALTH RELATED
QUALITY OF LIFE DURING THE PANDEMIC SEASON 2009-2010 IN SPAIN
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OBJECTIVES: The aim of this study was to estimate the impact on HRQL of in- and
outpatients with confirmed Influenza A H1N1/2009, and estimate the associated
burden during the pandemic season 2009-2010. METHODS: Longitudinal, observa-
tional, multi-centre study of in- and outpatients with confirmed diagnosis of influ-
enza A H1N1/2009 in Spain. Baseline sociodemographic and clinical characteristics
and HRQL were assessed at the hospitalization or primary care visit recruitment.
HRQL in the previous 7 days was also assessed. A sub-sample of patients was
followed-up after recovery. The EQ-5D was used to describe HRQL and calculate
utilities. HRQL loss was evaluated among in- and outpatients by several character-
istics. Loss of Quality Adjusted Life Years (QALYs) was calculated at individual level
taking into account the length of the influenza syndrome. Global burden was esti-
mated from the total number of cases in Spain. RESULTS: A total of 432 inpatients
and 563 outpatients were included and 145 and 184, respectively, were followed-
up. EQ-5D index previous to influenza was 0.81 (CI95% 0.78–0.84) for inpatients and
0.93 (CI95% 0.91–0.94) for outpatients. During influenza, HRQL loss was -0.58(0.02)
for inpatients, and -0.43(0.02) for outpatients. For all patients, Pain/discomfort and
Usual Activities were the most affected dimensions presenting a deterioration
from 73% to 80%. The individual QALYs loss for inpatients was 0.0135 and for
outpatients, 0.0098. In contrasts, the global burden was 41 (inpatients) and 7,283
QALYs (outpatients). CONCLUSIONS: Influenza H1N1/2009 supposed a significant,
but transient, impact on patients HRQL. The pandemic produced a considerable
QALYs loss, especially among less severe patients, comparable with the burden of
some chronic diseases and higher than that of other infectious diseases.
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DOES CONNECTING TOBACCO CESSATION INTERVENTION IN TUBERCULOSIS
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OBJECTIVES:There is growing evidence in the literature supporting the association
between tobacco smoking and poor tuberculosis (TB) treatment outcomes. Con-
necting TB and tobacco cessation interventions has been strongly advocated as this
may produce significant benefits. However, no study has documented the impact
of such integration on health-related quality of life (HRQoL). The objective of the
study was to document the impact of an integrated TB directly observed therapy
short-course (DOTS) plus smoking cessation intervention (SCI) on HRQoL.
METHODS: This was a non-randomized controlled study (quasi experimental de-
sign) involving 120 TB patients who were current smokers at the time of TB diag-
nosis. Patients were assigned to either of two groups: conventional TB-DOTS plus
smoking cessation intervention (SCIDOTS group) or conventional TB-DOTS only
(DOTS group). The effects of the novel intervention on HRQoL were measured using
EQ-5D questionnaire. Two-way repeated measure ANOVA was used to examine
the effects. RESULTS: When compared, participants who received the integrated
intervention had a better HRQoL than those who received the conventional TB care.
The SCIDOTS group had a significantly greater increase in EQ-5D utility score than
the DOTS group during 6 months follow-up (mean SD 0.98 0.08 vs. 0.91 0.14,
p  0.006). Similarly, the mean scores for EQ-VAS showed a consistently similar
trend as the EQ-5D indices, with the scores increasing over the course of TB treat-
ment. Furthermore, for the EQ-VAS, there were significant main effects for group [F
(1, 84)  4.91, p  0.029, 2  0.06], time [F (2, 168)  139.50, p  0.001, 2  0.62]
and group x time interaction [F (2, 168)  13.89, p  0.001, 2  0.14].
CONCLUSIONS: This study provides evidence that an integrated TB-tobacco treat-
ment strategy could potentially improve overall quality of life outcomes among TB
patients who are smokers.
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OBJECTIVES: Health-related quality of life (HRQL) is modulated by the type and
frequency of symptoms experienced in daily life. Such a relationship is likely de-
termined in part by treatment regimen and health care system. We studied how
symptoms reported by HIV patients under PI- vs. NNTI-based HAART relate to
different HRQL dimensions on the PROQOL-HIV questionnaire. METHODS: N424
HAART patients (4110 yrs., 36% females, 8 countries), without comorbidity, com-
pleted a 31-symptom HIV checklist (presence/absence) and the PROQOL-HIV ques-
tionnaire (43 Likert items, 8 dimensions). Hierarchical cluster analysis uncovered
the structure of symptoms experienced in patients under PI (N242) or NNTI
(N182) regimen. Canonical correlation analysis (CCA) showed the relationships
between symptoms and HRQL dimensions, and between-country variations.
RESULTS: A common group of symptoms related to body fat (lipodystrophy) and
weight changes was shared by patients across treatment regimens. However, fre-
quency of some side-effects–sleep disturbance, headache, diarrhea, nausea, fa-
tigue and pain–were more frequent with PI regimens. The CCA showed that a) body
fat change, sleep disturbance, skin problems and abdominal pain symptoms were
related to the ‘body change’ and ‘physical health and symptoms’ HRQL dimensions
(canonical correlation, 0.78), and b) symptoms concerning physical appearance
were related to the ‘stigma’ dimension, whereas other side-effects did not. It also
replicated a common finding whereby patients from Western countries (France,
Australia, USA) tend to report better HRQL compared to Chinese and Cambodian
patients, the latter also experiencing more symptoms due to IP-based treatment.
CONCLUSIONS: Treatment-related symptoms aligned with PROQOL-HIV dimen-
sions and known differences between countries. The use of CCA as an exploratory
multiple endpoints model helped to unravel complex relationships between symp-
toms and HRQL facets. The choice of treatment strategies should rely not only on
symptoms experience, but also account for their relations to HRQL in light of vary-
ing access to care.
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OBJECTIVES:New protease inhibitors (PIs) significantly improve sustained virolog-
ical responses (SVRs) in patients with genotype 1 chronic hepatitis C. However,
treatment (Tx) in prior null-responders with advanced fibrosis often results in
failure to achieve SVR and development of resistant mutations. Emerging quadru-
ple Tx adding two direct antiviral agents may achieve SVR in nearly all of these
patients. This study aimed to compare two strategies: 1) treating prior null-re-
sponders with fibrosis stage 3 (F3) or stage 4 (F4) with telaprevir  peginterferon 
ribavirin (“TPR strategy”) versus 2) withholding Tx until more effective antiviral
agents become available (“Wait strategy”). METHODS: The MONARCH Hepatitis C
cost-effectiveness model was used to project outcomes in cohorts of 55-year-old
prior null-responders using published dynamic transition rates for disease pro-
gression. “TPR strategy” achieves SVR in 42% of F3 and in 14% of F4 patients. In
the Wait strategy, patients would wait for 5 years and then initiate quadruple Tx
yielding 90% SVR. Quadruple Tx would be used as rescue in patients failing
“TPR”, 70% of whom would harbor virus resistant to PIs. Patient outcome in
terms of SVR and quality-adjusted-life years (QALYs) were assessed 10 years there-
after. Benefits were discounted at 3.5%. RESULTS: Projected SVR rates were higher
with the “Wait strategy” (76% and 65% for F3 and F4 respectively) than “TPR
strategy” (50% and 30% for F3 and F4 respectively). Per-patient expected QALYs
were higher for “Wait strategy” than “TPR strategy”; 8.59 versus 8.47 QALYs in
F3 patients and 7.5 versus 6.7 QALYs in F4 patients. The Wait strategy was asso-
ciated with one-third fewer re-treatments. CONCLUSIONS:Waiting for future qua-
druple antiviral therapy maximized the predicted health benefit both in terms of
response (SVR) and QALYs; furthermore, the reduction in re-treatments associated
with the Wait strategy is noteworthy given the likely high cost of triple therapy.
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MODELLING THE IMPACT OF EXTENDED VACCINATION STRATEGIES ON THE
EPIDEMIOLOGY OF PERTUSSIS
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OBJECTIVES: To investigate the optimal pertussis booster vaccination strategy for
the The Netherlands and to explore the impact of different assumptions for pa-
rameters surrounded by uncertainty. METHODS: The authors designed a realistic
age-structured deterministic model. Assuming a steady state situation and cor-
recting for underreporting, the model was calibrated using notification data from
the period 1996-2000. Several sensitivity analyses were performed including vary-
ing the age of a booster dose (or multiple booster doses), expected vaccine uptake,
duration of protection after natural infection, underreporting factors, contact func-
tion, and transmission probabilities. RESULTS: The results indicated that the op-
timal age of an additional booster dose is in the range of 10-15 years, and imple-
mentation of this booster dose will reduce both symptomatic and asymptomatic
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